See more : Green Hygienics Holdings Inc. (GRYN) Income Statement Analysis – Financial Results
Complete financial analysis of Pacira BioSciences, Inc. (PCRX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Pacira BioSciences, Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
You may be interested
- Nozaki Insatsu Shigyo Co., Ltd. (7919.T) Income Statement Analysis – Financial Results
- Phoenix Copper Limited (PXCLY) Income Statement Analysis – Financial Results
- Kangping Technology (Suzhou) Co., Ltd. (300907.SZ) Income Statement Analysis – Financial Results
- BYBON Group Company Limited (300736.SZ) Income Statement Analysis – Financial Results
- Intact Financial Corporation (IFC.TO) Income Statement Analysis – Financial Results
Pacira BioSciences, Inc. (PCRX)
About Pacira BioSciences, Inc.
Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature only to targeted nerves. It also develops proprietary multivesicular liposome, a drug delivery technology that encapsulates drugs without altering their molecular structure. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Tampa, Florida.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 674.98M | 666.82M | 541.53M | 420.83M | 421.03M | 337.28M | 286.63M | 276.37M | 249.00M | 197.67M | 85.55M | 39.08M | 15.69M | 14.56M | 15.01M | 13.93M |
| Cost of Revenue | 184.67M | 199.30M | 140.26M | 117.33M | 106.71M | 86.85M | 87.92M | 110.10M | 71.84M | 77.44M | 54.77M | 32.14M | 16.74M | 12.28M | 12.30M | 17.46M |
| Gross Profit | 490.31M | 467.53M | 401.28M | 303.50M | 314.31M | 250.43M | 198.72M | 166.27M | 177.16M | 120.23M | 30.78M | 6.95M | -1.05M | 2.29M | 2.71M | -3.54M |
| Gross Profit Ratio | 72.64% | 70.11% | 74.10% | 72.12% | 74.65% | 74.25% | 69.33% | 60.16% | 71.15% | 60.82% | 35.98% | 17.77% | -6.69% | 15.70% | 18.03% | -25.41% |
| Research & Development | 76.26M | 84.80M | 55.55M | 59.42M | 72.12M | 55.69M | 57.29M | 45.68M | 28.66M | 18.73M | 21.56M | 9.94M | 14.87M | 18.63M | 26.23M | 33.21M |
| General & Administrative | 116.40M | 109.52M | 88.32M | 74.83M | 71.12M | 70.16M | 66.69M | 63.40M | 61.31M | 41.65M | 20.96M | 15.97M | 20.16M | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 153.04M | 145.00M | 111.02M | 118.68M | 129.66M | 107.11M | 94.80M | 89.22M | 77.73M | 65.01M | 41.55M | 30.33M | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 269.44M | 254.52M | 199.35M | 193.52M | 200.78M | 177.27M | 161.49M | 152.61M | 139.04M | 106.66M | 62.51M | 46.31M | 20.16M | 6.03M | 5.02M | 8.61M |
| Other Expenses | 56.94M | 57.29M | 13.55M | 7.87M | 5.70M | -888.00K | 167.00K | -82.00K | -165.00K | -159.00K | -47.00K | -111.00K | 3.02M | 6.03M | 5.02M | 8.61M |
| Operating Expenses | 402.63M | 396.60M | 268.44M | 260.80M | 278.60M | 232.95M | 218.78M | 198.29M | 167.71M | 125.39M | 84.07M | 56.24M | 35.03M | 24.66M | 31.25M | 41.83M |
| Cost & Expenses | 587.30M | 595.90M | 408.70M | 378.13M | 385.32M | 319.80M | 306.70M | 308.40M | 239.54M | 202.83M | 138.84M | 88.38M | 51.77M | 36.93M | 43.55M | 59.29M |
| Interest Income | 11.44M | 4.54M | 896.00K | 4.63M | 7.38M | 6.50M | 4.08M | 1.32M | 678.00K | 382.00K | 259.00K | 275.00K | 255.00K | 146.00K | 77.00K | 235.00K |
| Interest Expense | 20.31M | 39.98M | 31.75M | 25.67M | 23.63M | 21.95M | 18.05M | 7.06M | 7.73M | 8.28M | 7.25M | 1.81M | 4.78M | 4.89M | 3.60M | 3.49M |
| Depreciation & Amortization | 75.57M | 91.50M | 28.55M | 19.91M | 19.58M | 13.17M | 13.83M | 12.92M | 11.48M | 10.04M | 5.75M | 5.65M | 4.31M | 4.25M | 4.43M | 3.83M |
| EBITDA | 157.58M | 144.78M | 118.47M | 71.42M | 55.29M | 33.06M | -10.59M | -17.86M | 21.39M | 5.09M | -50.73M | -44.55M | -34.23M | -19.12M | -24.12M | -41.53M |
| EBITDA Ratio | 23.35% | 18.22% | 26.71% | 15.89% | 10.41% | 6.85% | -5.52% | -11.14% | 4.00% | -2.50% | -55.32% | -125.71% | -185.14% | -124.20% | -163.15% | -296.65% |
| Operating Income | 87.68M | 60.02M | 131.07M | 46.35M | 38.11M | 15.92M | -24.94M | -32.02M | 9.46M | -5.17M | -53.29M | -49.30M | -39.10M | -22.37M | -28.55M | -45.36M |
| Operating Income Ratio | 12.99% | 9.00% | 24.20% | 11.01% | 9.05% | 4.72% | -8.70% | -11.59% | 3.80% | -2.61% | -62.29% | -126.13% | -249.23% | -153.63% | -190.24% | -325.77% |
| Total Other Income/Expenses | -25.97M | -46.72M | -33.52M | -26.26M | -26.66M | -16.34M | -17.53M | -5.82M | -7.34M | -8.38M | -11.06M | -2.98M | -4.23M | -4.78M | -3.16M | 3.50M |
| Income Before Tax | 61.70M | 13.30M | 56.40M | 20.09M | -10.75M | -425.00K | -42.47M | -37.84M | 2.12M | -13.54M | -64.35M | -52.28M | -43.33M | -27.15M | -28.18M | -45.59M |
| Income Before Tax Ratio | 9.14% | 1.99% | 10.42% | 4.77% | -2.55% | -0.13% | -14.82% | -13.69% | 0.85% | -6.85% | -75.22% | -133.77% | -276.17% | -186.44% | -187.80% | -327.38% |
| Income Tax Expense | 19.75M | -2.61M | 14.42M | -125.43M | 268.00K | 46.00K | 140.00K | 105.00K | 264.00K | 173.00K | -442.00K | -3.95M | 7.25M | 4.78M | 3.16M | -3.50M |
| Net Income | 41.96M | 15.91M | 41.98M | 145.52M | -11.02M | -471.00K | -42.61M | -37.95M | 1.86M | -13.72M | -63.91M | -52.28M | -43.33M | -27.15M | -31.71M | -41.86M |
| Net Income Ratio | 6.22% | 2.39% | 7.75% | 34.58% | -2.62% | -0.14% | -14.87% | -13.73% | 0.75% | -6.94% | -74.70% | -133.77% | -276.17% | -186.44% | -211.30% | -300.62% |
| EPS | 0.91 | 0.35 | 0.95 | 3.41 | -0.27 | -0.01 | -1.07 | -1.02 | 0.05 | -0.39 | -1.93 | -1.72 | -2.64 | -1.58 | -55.32 | -79.23 |
| EPS Diluted | 0.81 | 0.34 | 0.92 | 3.33 | -0.27 | -0.01 | -1.07 | -1.02 | 0.04 | -0.39 | -1.93 | -1.72 | -2.64 | -1.58 | -55.32 | -79.23 |
| Weighted Avg Shares Out | 46.22M | 45.52M | 44.26M | 42.67M | 41.51M | 40.91M | 39.81M | 37.20M | 36.54M | 35.17M | 33.11M | 30.33M | 16.44M | 17.23M | 573.12K | 528.36K |
| Weighted Avg Shares Out (Dil) | 51.98M | 46.54M | 45.63M | 43.68M | 41.51M | 40.91M | 39.81M | 37.24M | 41.30M | 35.30M | 33.18M | 30.33M | 16.44M | 17.23M | 573.12K | 528.36K |
Pacira BioSciences Reports Second Quarter 2024 Financial Results
-- Conference call today at 4:30 p.m. ET -- TAMPA, Fla., July 30, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today reported financial results...
3 Biotech Stocks to Buy on the Dip: July 2024
The biotechnology sector doesn't need to rizz up investors, as the kids like to say. Unless the human desire to find solutions for vexing conditions and diseases somehow goes away in a dystopian paradigm, the ecosystem is safe.
Should Value Investors Buy Pacira BioSciences (PCRX) Stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong...
Pacira (PCRX) Rises on Proposed Exparel Reimbursement Plan
Pacira (PCRX) gains upon the inclusion of Exparel as one of only six qualifying non-opioid drugs to treat postsurgical pain in the proposed reimbursement rule, if adopted.
Centers for Medicare and Medicaid Propose New Reimbursement for EXPAREL in All Outpatient Surgical Environments Beginning January 1, 2025
-- Proposed Hospital Outpatient Prospective Payment and Ambulatory Surgical Center Payment System Rule extends separate payment from ambulatory surgical centers to include the hospital outpatient environment –
Top 5 Health Care Stocks That May Explode In July
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
This Charter Communications Analyst Turns Bearish; Here Are Top 5 Downgrades For Wednesday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.
Why Is Pacira (PCRX) Up 1.7% Since Last Earnings Report?
Pacira (PCRX) reported earnings 30 days ago. What's next for the stock?
Pacira BioSciences to Participate in Fireside Chat at the 2024 Jefferies Global Healthcare Conference
TAMPA, Fla., May 30, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will participate in an analyst-led fireside chat at the 2024 Jefferies Global Healthcare Conference at 11:00 AM ET on Thursday, June 6, 2024...
Pacira BioSciences, Inc. Announces Pricing of $250.0 Million Aggregate Principal Amount of 2.125% Convertible Senior Notes due 2029
TAMPA, Fla., May 10, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX) today announced the pricing of $250.0 million aggregate principal amount of convertible senior notes due 2029 (the “notes”) in a private placement to qualified institutional buyers pursuant...
Source: https://incomestatements.info
Category: Stock Reports